Results From the Genetic Information and Family Testing Study: A Cluster-Randomized Trial

S Steven J. Katz (University of Michigan Medical School, Ann Arbor, MI) T Timothy P. Hofer (Department of Internal Medicine, University of Michigan, Ann Arbor, MI) P Paul Abrahamse (University of Michigan, Ann Arbor, MI) R Rebecca R. Courser (Department of Internal Medicine, University of Michigan, Ann Arbor, MI) R Rachel Hodan (Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA) R Rachel S. Tocco (Department of Psychiatry, University of Michigan, Ann Arbor, MI) S Sonia Rios-Ventura (Stanford School of Medicine, Stanford, CA) K Kevin C. Ward (Emory University, Rollins School of Public Health, Atlanta, GA) A Ann S. Hamilton (University of Southern California, Los Angeles, CA) M Melissa K. Frey (Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY) L Lawrence C. An (University of Michigan, Ann Arbor, MI) A Allison W. Kurian (Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA)

Abstract

PURPOSE Cascade genetic testing in families with hereditary cancer syndromes is an important strategy to reduce the burden of cancer, but testing of relatives is low. Direct engagement of relatives through cancer survivors is a promising approach to bridge this gap. METHODS We conducted a population-based cluster-randomized clinical trial (Genetic Information and Family Testing [GIFT]) of an online, direct-to-family, cancer genetic education and communication tool including the offer of home testing to adult relatives of cancer survivors diagnosed in 2018-2019 who carried a pathogenic variant. We selected patients through SEER and surveyed them for eligibility followed by a trial invitation. Two features were randomized: assistance from a human navigator (yes, no) and testing cost (free v $50). We hypothesized that the fraction of relatives tested in a family (primary outcome) would be higher with a navigator and free testing. RESULTS Four thousand three hundred patients were surveyed and 2,285 responded (53.1%); 2,006 eligible respondents were invited (87.8%) and 414 enrolled (20.6%). Enrolled patients reported a total of 4,946 first- and second-degree relatives (mean, 12.3; standard deviation [SD], 8.6); they invited 948 relatives (19.2%) and 303 enrolled (32.0%). Most enrolled relatives ordered testing (267, 91.3%); more than double were tested in the free versus $50 arm (odds ratio [OR], 2.5 [1.6-3.9]), but the baseline fraction tested was low at 0.03 and thus the absolute increase was modest (0.04 [95% CI, 0.02 to 0.05]). We did not find evidence for increased testing in the navigation arm (OR, 1.3 [0.8-2.1]). CONCLUSION GIFT is a promising blueprint for online cascade genetic education and testing. Results suggest that a low-cost, population-level intervention could be deployed without a human navigator. Additional intervention strategies are needed to increase the modest invitation and testing uptake observed in this study.

Article Details

Volume / Issue Vol. 44, Issue 13
Published May 01, 2026
Pages 1216-1224
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (12)

S

Steven J. Katz

University of Michigan Medical School, Ann Arbor, MI

T

Timothy P. Hofer

Department of Internal Medicine, University of Michigan, Ann Arbor, MI

P

Paul Abrahamse

University of Michigan, Ann Arbor, MI

R

Rebecca R. Courser

Department of Internal Medicine, University of Michigan, Ann Arbor, MI

R

Rachel Hodan

Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA

R

Rachel S. Tocco

Department of Psychiatry, University of Michigan, Ann Arbor, MI

S

Sonia Rios-Ventura

Stanford School of Medicine, Stanford, CA

K

Kevin C. Ward

Emory University, Rollins School of Public Health, Atlanta, GA

A

Ann S. Hamilton

University of Southern California, Los Angeles, CA

M

Melissa K. Frey

Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY

L

Lawrence C. An

University of Michigan, Ann Arbor, MI

A

Allison W. Kurian

Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA